

Regular Session, 2013

HOUSE BILL NO. 15

BY REPRESENTATIVE MACK

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

CONTROLLED SUBSTANCES: Adds certain compounds to the Schedule I classification of controlled dangerous substances

1 AN ACT

2 To amend and reenact R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F) and to enact R.S.
3 40:961(26.1), relative to controlled dangerous substances; to provide with respect to
4 certain chemical groups within the cathinone Schedule I stimulants; to add
5 substances to the listing of synthetic cannabinoids in Schedule I; to provide for
6 definitions; to provide for certain exceptions; and to provide for related matters.

7 Be it enacted by the Legislature of Louisiana:

8 Section 1. R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F) are hereby amended and
9 reenacted and R.S. 40:961(26.1) is hereby enacted to read as follows:

10 §961. Definitions

11 As used in this Part, the following terms shall have the meaning ascribed to
12 them in this Section unless the context clearly indicates otherwise:

13 * * *

14 (26.1) "Nitrogen-heterocyclic analog" means a nitrogen-heterocyclic analog
15 of a synthetic cannabinoid which has a single carbon atom in a cyclic structure of a
16 compound replaced by a nitrogen atom.

17 * * *

1 §964. Composition of schedules

2 Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.
3 40:962, consist of the following drugs or other substances, by whatever official
4 name, common or usual name, chemical name, or brand name designated:

5 SCHEDULE I

6 * * *

7 E. Stimulants. Unless specifically excepted, or contained within a
8 pharmaceutical product approved by the United States Federal Food and Drug
9 Administration, or unless listed in another schedule, any material, compound,
10 mixture, or preparation which contains any quantity of the following substances
11 having a stimulant effect on the central nervous system including its salts, isomers,
12 esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such
13 salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible
14 within the specific chemical designation:

15 * * *

16 (9) 2-amino-1-phenyl-1-propanone (cathinone) or variation in any of the
17 following ways:

18 (i) By substitution in the phenyl ring to any extent with alkyl, hydroxyl
19 alkoxy, alkylendioxy, haloalkyl or halide substituents, whether or not further
20 substituted in the phenyl ring by one or more other univalent substituents.

21 (ii) By substitution at the 3-position with an alkyl substituent.

22 (iii) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, ~~or~~
23 ~~benzyl groups, or methoxybenzyl groups,~~ or by inclusion of the 2-amino nitrogen
24 atom in a cyclic structure.

25 F. Synthetic cannabinoids. Unless specifically excepted, or contained within
26 a pharmaceutical product approved by the United States Food and Drug
27 Administration, or unless listed in another schedule, any material, compound,
28 mixture, or preparation, which contains any quantity of a synthetic cannabinoid
29 found to be in any of the following chemical groups, or any of those groups which

1 contain any synthetic cannabinoid salts, isomers, ~~or~~ salts of isomers, or nitrogen-
2 heterocyclic analogs, whenever the existence of such salts, isomers, ~~or~~ salts of
3 isomers, or nitrogen-heterocyclic analogs is possible within the specific chemical
4 designation, ~~including all synthetic cannabinoid chemical analogues in such groups:~~

5 (1) Naphthoylindoles: any compound containing a 3-(1-naphthoyl)indole
6 structure, whether or not substituted in the indole ring to any extent or the naphthyl
7 ring to any extent.

8 (2) Naphthylmethyloindoles: any compound containing a 1-H-indol-3-yl-(1-
9 naphthyl)methane structure, whether or not substituted in the indole ring to any
10 extent or the naphthyl ring to any extent.

11 (3) Naphthoylpyrroles: any compound containing a 3-(1-naphthoyl)pyrrole
12 structure, whether or not substituted in the pyrrole ring to any extent or the naphthyl
13 ring to any extent.

14 (4) Naphthylmethyloindenes: any compound containing a 1-(1-
15 naphthylmethyl)indene structure, whether or not substituted in the indene ring to any
16 extent or the naphthyl ring to any extent.

17 (5) Phenylacetyloindoles: any compound containing a 3-phenylacetyloindole
18 structure, whether or not substituted in the indole ring to any extent or the phenyl
19 ring to any extent.

20 (6) Cyclohexylphenols: any compound containing a 2-(3-
21 hydroxycyclohexyl)phenol structure, whether or not substituted in the cyclohexyl
22 ring to any extent or the phenyl ring to any extent.

23 ~~(7) Dibenzopyrans whether or not substituted in the cyclohexyl ring to any~~
24 ~~extent or the phenyl ring to any extent.~~

25 ~~(8)~~(7) Benzoyloindoles: any compound containing a 3-(benzoyl)indole
26 structure, whether or not substituted in the indole ring to any extent or the phenyl
27 ring to any extent.

Proposed law adds certain chemical groups to the Schedule I listing of stimulants known as cathinones and adds additional substances to the Schedule I listing of synthetic cannabinoids.

Proposed law provides a definition of "nitrogen-heterocyclic analog".

(Amends R.S. 40:964(Schedule I)(E)(9)(i) and (iii) and (F); Adds R.S. 40:961(26.1))